Bendell JC, Sauri T, Gracián AC, et al. - Researchers focused on the effectiveness of vanucizumab plus modified (m)FOLFOX-6 (folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin) vs bevacizumab/mFOLFOX-6 for first-line metastatic colorectal cancer (mCRC) in this phase II trial enrolling 189 patients. mFOLFOX-6 was given to all participants and also vanucizumab 2,000 mg or bevacizumab 5 mg/kg every other week was administered using randomization 1:1. For eight cycles, patients received oxaliplatin; other agents were continued until disease progression or unacceptable toxicity for a maximum of 24 months. Investigator-evaluated progression-free survival (PFS) was considered as the primary endpoint. They found no improvement in PFS was brought about by vanucizumab/mFOLFOX-6. Also, increased rates of antiangiogenic toxicity were reported in relation to vanucizumab/mFOLFOX-6 vs bevacizumab/mFOLFOX-6. Experts concluded that angiopoetin-2 is not a relevant treatment target in first-line mCRC.